EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse

Amy Flaxman, Sarah Sebastian, Sofia Appelberg, Kuan M Cha, Marta Ulaszewska, Jyothi Purushotham, Ciaran Gilbride, Hannah Sharpe, Alexandra J Spencer, Sagida Bibi, Daniel Wright iD, Isabel Schmidt und 6 weitere

PLOS Pathogens · 2024

DOI: 10.1371/journal.ppat.1012262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Amy Flaxman und 17 weiteren Autor:innen. Beteiligte Einrichtung: Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Ebolavirus, Lassa virus, Marburgvirus, Hemorrhagic Fever, Ebola. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Department of Health and Social Care (DHSC), MRC, European Union’s Horizon 2020 Research & Innovation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Viral haemorrhagic fevers (VHF) pose a significant threat to human health. In recent years, VHF outbreaks caused by Ebola, Marburg and Lassa viruses have caused substantial morbidity and mortality in West and Central Africa. In 2022, an Ebola disease outbreak in Uganda caused by Sudan virus resulted in 164 cases with 55 deaths. In 2023, a Marburg disease outbreak was confirmed in Equatorial Guinea and Tanzania resulting in over 49 confirmed or suspected cases; 41 of which were fatal. There are no clearly defined correlates of protection against these VHF, impeding targeted vaccine development. Any vaccine developed should therefore induce strong and preferably long-lasting humoral and cellular immunity against these viruses. Ideally this immunity should also cross-protect against viral variants, which are known to circulate in animal reservoirs and cause human disease. We have utilized two viral vectored vaccine platforms, an adenovirus (ChAdOx1) and Modified Vaccinia Ankara (MVA), to develop a multi-pathogen vaccine regime against three filoviruses (Ebola virus, Sudan virus, Marburg virus) and an arenavirus (Lassa virus). These platform technologies have consistently demonstrated the capability to induce robust cellular and humoral antigen-specific immunity in humans, most recently in the rollout of the licensed ChAdOx1-nCoV19/AZD1222. Here, we show that our multi-pathogen vaccines elicit strong cellular and humoral immunity, induce a diverse range of chemokines and cytokines, and most importantly, confers protection after lethal Ebola virus, Sudan virus and Marburg virus challenges in a small animal model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EbolavirusLassa virusMarburgvirusHemorrhagic Fever, EbolaLassa FeverMarburg Virus DiseaseAnimalsMiceViral VaccinesHumansVaccinationFemaleAntibodies, ViralImmunogenicity, VaccineEbola Vaccines

Substanzen

Viral VaccinesAntibodies, ViralEbola Vaccines

Autor:innen und Institutionen

  • Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Public Health Agency of Sweden, Solna, Sweden.
  • Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom.
  • Chinese Academy of Medical Science (CAMS) Oxford Institute, University of Oxford, Oxford, United Kingdom.

ORCID-Profile: Daniel Wright, Teresa Lambe

Förderung

  • The Department of Health and Social Care (DHSC)
  • MRC
  • European Union’s Horizon 2020 Research & Innovation Program
  • Innovate UK
  • Medical Research Council
  • Horizon 2020 Research and Innovation Program

Zitieren

APA

Flaxman, A., Sebastian, S., Appelberg, S., Cha, K. M., Ulaszewska, M., Purushotham, J., Gilbride, C., Sharpe, H., Spencer, A. J., Bibi, S., Wright, D., Schmidt, I., Dowall, S., Easterbrook, L., Findlay-Wilson, S., Gilbert, S., Mirazimi, A., & Lambe, T. (2024). Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012262

Vancouver

Flaxman A, Sebastian S, Appelberg S, Cha KM, Ulaszewska M, Purushotham J, et al. Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012262

BibTeX
@article{Flaxman2024,
  author = {Flaxman, Amy and Sebastian, Sarah and Appelberg, Sofia and Cha, Kuan M and Ulaszewska, Marta and Purushotham, Jyothi and Gilbride, Ciaran and Sharpe, Hannah and Spencer, Alexandra J and Bibi, Sagida and Wright, Daniel and Schmidt, Isabel and Dowall, Stuart and Easterbrook, Linda and Findlay-Wilson, Stephen and Gilbert, Sarah and Mirazimi, Ali and Lambe, Teresa},
  title = {Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse},
  journal = {PLOS Pathogens},
  year = {2024},
  doi = {10.1371/journal.ppat.1012262}
}
Kostenlos starten →